Trial Profile
Effectiveness and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 01 May 2020 Results (n=2654) of a retrospective and a sub-group analysis from two large observational studies: NCT01077258 and NCT01078090 assessing whether previous biologic therapy influenced the impact of concomitant Methotrexate in patients initiating treatment with adalimumab during routine clinical practice published in the Medicine
- 07 Mar 2013 Planned End Date changed from 1 Jun 2014 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.